Endothelial C-type natriuretic peptide maintains vascular homeostasis

Journal of Clinical Investigation

Volumn 124, Issue 9, 2014, Pages 4039-4051

  Moyes, Amie J ^a   Khambata, Rayomand S ^a   Villar, Inmaculada ^a   Bubb, Kristen J ^a   Baliga, Reshma S ^a   Lumsden, Natalie G ^a   Xiao, Fang ^a   Gane, Paul J ^b   Rebstock, Anne Sophie ^b   Worthington, Roberta J ^b   Simone, Michela I ^b,f   Mota, Filipa ^b   Rivilla, Fernando ^c   Vallejo, Susana ^d   Peiró, Concepción ^d   Sánchez Ferrer, Carlos F ^d   Djordjevic, Snezana ^e   Caulfield, Mark J ^a   MacAllister, Raymond J ^e   Selwood, David L ^b   Ahluwalia, Amrita ^a   Hobbs, Adrian J ^a   more..

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c HOSPITAL RAMÓN Y CAJAL   (Spain)

^d UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; NATRIURETIC PEPTIDE RECEPTOR C; NATRIURETIC PEPTIDE TYPE C; CALCIUM;

ANEURYSM; ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA; ARTERY RESISTANCE; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; B LYMPHOCYTE; BLOOD PRESSURE REGULATION; BLOOD VESSEL REACTIVITY; BLOOD VESSEL TONE; CELL POPULATION; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; EVALUATION STUDY; FEMALE; GENE; GENE DELETION; GENE LOCUS; GENETIC ASSOCIATION; HOMEOSTASIS; HYPERTENSION; KNOCKOUT MOUSE; LEUKOCYTE; LEUKOCYTE ROLLING; MALE; MEAN ARTERIAL PRESSURE; MESENTERIC ARTERY; MONOCYTE; MOUSE; NEUTROPHIL; NONHUMAN; NPPC GENE; NPR3 GENE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; T LYMPHOCYTE; VASCULAR ENDOTHELIUM; VASCULAR HOMEOSTASIS; VASCULAR SMOOTH MUSCLE; VASODILATATION; WILD TYPE; ANIMAL; AORTIC ANEURYSM; BLOOD PRESSURE; C57BL MOUSE; DRUG EFFECTS; METABOLISM; PHYSIOLOGY; RAT; THROMBOCYTE;

ANIMALS; AORTIC ANEURYSM; ATHEROSCLEROSIS; BLOOD PLATELETS; BLOOD PRESSURE; CALCIUM; ENDOTHELIUM, VASCULAR; FEMALE; HOMEOSTASIS; LEUKOCYTES; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MUSCLE, SMOOTH, VASCULAR; NATRIURETIC PEPTIDE, C-TYPE; RATS; VASODILATION;

EID: 84907007263     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI74281     Document Type: Article

References (75)

1. Vane JR, Anggard EE, Botting RM. Regulatory functions of the vascular endothelium. N Engl J Med. 1990;323(1): 27-36.
2. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med. 1993;329(27): 2002-2012.
3. Celermajer DS, Sorensen KE, Bull C, Robinson J, Deanfield JE. Endothelium-dependent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interaction. J Am Coll Cardiol. 1994;24(6): 1468-1474.
4. Widlansky ME, Gokce N, Keaney JF, Keaney JF Jr, Vita JA. The clinical implications of endothelial dysfunction. J Am Coll Cardiol. 2003;42(7): 1149-1160.
5. Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci U S A. 1987;84(24): 9265-9269.
6. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature. 1987;327(6122): 524-526.
7. Busse R, Edwards G, Feletou M, Fleming I, Vanhoutte PM, Weston AH. EDHF: bringing the concepts together. Trends Pharmacol Sci. 2002;23(8): 374-380.
8. McCulloch AI, Randall MD. Sex differences in the relative contributions of nitric oxide and EDHF to agonist-stimulated endothelium- dependent relaxations in the rat isolated mesenteric arterial bed. Br J Pharmacol. 1998;123(8): 1700-1706.
9. Scotland RS, et al. Investigation of vascular responses in endothelial nitric oxide synthase/ cyclooxygenase-1 double-knockout mice: key role for endothelium-derived hyperpolarizing factor in the regulation of blood pressure in vivo. Circulation. 2005;111(6): 796-803.
10. Barrett-Connor E. Sex differences in coronary heart disease. Why are women so superior? The 1995 Ancel Keys Lecture. Circulation. 1997;95(1): 252-264.
11. de Bold AJ. Atrial natriuretic factor: a hormone produced by the heart. Science. 1985;230(4727): 767-770.
12. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med. 1998;339(5): 321-328.
13. Chusho H, et al. Dwarfism and early death in mice lacking C-type natriuretic peptide. Proc Natl Acad Sci U S A. 2001;98(7): 4016-4021.
14. Komatsu Y, et al. Significance of C-type natriuretic peptide (CNP) in endochondral ossification: analysis of CNP knockout mice. J Bone Miner Metab. 2002;20(6): 331-336.
15. Chen HH, Burnett JC, Burnett JC J.R. C-type natriuretic peptide: the endothelial component of the natriuretic peptide system. J Cardiovasc Pharmacol. 1998;32(suppl 3): S22-S28.
16. Ahluwalia A, Hobbs AJ. Endothelium-derived C-type natriuretic peptide: more than just a hyperpolarizing factor. Trends Pharmacol Sci. 2005;26(3): 162-167.
17. Suga S, et al. Cytokine-induced C-type natriuretic peptide (CNP) secretion from vascular endothelial cells-evidence for CNP as a novel autocrine/ paracrine regulator from endothelial cells. Endocrinology. 1993;133(6): 3038-3041.
18. Stingo AJ, et al. Presence of C-type natriuretic peptide in cultured human endothelial cells and plasM.A. Am J Physiol. 1992;263(4 pt 2): H1318-H1321.
19. Sauer B, Henderson N. Site-specific DNA recombination in mammalian cells by the Cre recombinase of bacteriophage P1. Proc Natl Acad Sci U S A. 1988;85(14): 5166-5170.
20. Mitchell JA, De NG, Warner TD, Vane J.R. Different patterns of release of endothelium-derived relaxing factor and prostacyclin. Br J Pharmacol. 1992;105(2): 485-489.
21. Morley D, Keefer LK. Nitric oxide/nucleophile complexes: a unique class of nitric oxidebased vasodilators. J Cardiovasc Pharmacol. 1993;22(suppl 7): S3-S9.
22. Lahiri MK, Kannankeril PJ, Goldberger JJ. Assessment of autonomic function in cardiovascular disease: physiological basis and prognostic implications. J Am Coll Cardiol. 2008;51(18): 1725-1733.
23. Potter LR, Yoder AR, Flora DR, Antos LK, Dickey DM. Natriuretic peptides: their structures, receptors, physiologic functions and therapeutic applications. Handb Exp Pharmacol. 2009;(191): 341-366.
24. Chauhan SD, Nilsson H, Ahluwalia A, Hobbs AJ. Release of C-type natriuretic peptide accounts for the biological activity of endothelium-derived hyperpolarizing factor. Proc Natl Acad Sci U S A. 2003;100(3): 1426-1431.
25. Villar IC, et al. Definitive role for natriuretic peptide receptor-C in mediating the vasorelaxant activity of C-type natriuretic peptide and endothelium-derived hyperpolarising factor. Cardiovasc Res. 2007;74(3): 515-525.
26. Matsukawa N, et al. The natriuretic peptide clearance receptor locally modulates the physiological effects of the natriuretic peptide system. Proc Natl Acad Sci U S A. 1999;96(13): 7403-7408.
27. Maack T, et al. Physiological role of silent receptors of atrial natriuretic factor. Science. 1987;238(4827): 675-678.
28. Tamura N, Doolittle LK, Hammer RE, Shelton JM, Richardson JA, Garbers DL. Critical roles of the guanylyl cyclase B receptor in endochondral ossification and development of female reproductive organs. Proc Natl Acad Sci U S A. 2004;101(49): 17300-17305.
29. Nakamura M, Arakawa N, Yoshida H, Makita S, Hiramori K. Vasodilatory effects of C-type natriuretic peptide on forearm resistance vessels are distinct from those of atrial natriuretic peptide in chronic heart failure. Circulation. 1994;90(3): 1210-1214.
30. Honing ML, Smits P, Morrison PJ, Burnett JC, Burnett JC Jr, Rabelink TJ. C-type natriuretic peptide-induced vasodilation is dependent on hyperpolarization in human forearm resistance vessels. Hypertension. 2001;37(4): 1179-1183.
31. Igaki T, et al. C-type natriuretic peptide in chronic renal failure and its action in humans. Kidney Int Suppl. 1996;55:S144-S147.
32. Stingo AJ, Clavell AL, Aarhus LL. Cardiovascular and renal actions of C-type natriuretic peptide. Am J Physiol. 1992;262(1 pt 2): H308-H312.
33. Clavell AL, Stingo AJ, Wei CM, Heublein DM, Burnett JC, Burnett JC J.R. C-type natriuretic peptide: a selective cardiovascular peptide. Am J Physiol. 1993;264(2 pt 2): R290-R295.
34. Seymour AA, Mathers PD, Abboa-Offei BE, Asaad MM, Weber H. Renal and depressor activity of C-natriuretic peptide in conscious monkeys: effects of enzyme inhibitors. J Cardiovasc Pharmacol. 1996;28(3): 397-401.
35. Trachte GJ. Depletion of natriuretic peptide C receptors eliminates inhibitory effects of C-type natriuretic peptide on evoked neurotransmitter efflux. J Pharmacol Exp Ther. 2000;294(1): 210-215.
36. Rose RA, Giles WR. Natriuretic peptide C receptor signalling in the heart and vasculature. J Physiol. 2008;586(2): 353-366.
37. Murthy KS, Teng BQ, Jin JG, Makhlouf GM. G protein-dependent activation of smooth muscle eNOS via natriuretic peptide clearance receptor. Am J Physiol Cell Physiol. 1998;275(6 pt 1): C1409-C1416.
38. Sciarretta S, et al. C2238 atrial natriuretic peptide molecular variant is associated with endothelial damage and dysfunction through natriuretic peptide receptor C signaling. Circ Res. 2013;112(10): 1355-1364.
39. Li Y, Sarkar O, Brochu M, Anand-Srivastava MB. Natriuretic peptide receptor-C attenuates hypertension in spontaneously hypertensive rats: role of nitroxidative stress and Gi proteins. Hypertension. 2014;63(4): 846-855.
40. Veale CA, et al. The discovery of non-basic atrial natriuretic peptide clearance receptor antagonists. Part 1. Bioorg Med Chem Lett. 2000;10(17): 1949-1952.
41. Ley K, Laudanna C, Cybulsky MI, Nourshargh S. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol. 2007;7(9): 678-689.
42. Michelson AD, et al. In vivo tracking of platelets: circulating degranulated platelets rapidly lose surface P-selectin but continue to circulate and function. Proc Natl Acad Sci U S A. 1996;93(21): 11877-11882.
43. Furman MI, et al. Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease. J Am Coll Cardiol. 1998;31(2): 352-358.
44. Mayadas TN, Johnson RC, Rayburn H, Hynes RO, Wagner DD. Leukocyte rolling and extravasation are severely compromised in P selectindeficient mice. Cell. 1993;74(3): 541-554.
45. Zhang SH, Reddick RL, Piedrahita JA, Maeda N. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science. 1992;258(5081): 468-471.
46. Plump AS, et al. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell. 1992;71(2): 343-353.
47. He X, Chow D, Martick MM, Garcia KC. Allosteric activation of a spring-loaded natriuretic peptide receptor dimer by hormone. Science. 2001;293(5535): 1657-1662.
48. Lipinski CA. Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods. 2000;44(3): 235-249.
49. Ehret GB, et al. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature. 2011;478(7367): 103-109.
50. Wu C, Wu F, Pan J, Morser J, Wu Q. Furin-mediated processing of Pro-C-type natriuretic peptide. J Biol Chem. 2003;278(28): 25847-25852.
51. Ono K, Mannami T, Baba S, Tomoike H, Suga S, Iwai N. A single-nucleotide polymorphism in C-type natriuretic peptide gene may be associated with hypertension. Hypertens Res. 2002;25(5): 727-730.
52. Pitzalis MV, et al. Allelic variants of natriuretic peptide receptor genes are associated with family history of hypertension and cardiovascular phenotype. J Hypertens. 2003;21(8): 1491-1496.
53. Aoi N, et al. Variable number of tandem repeat of the 5'-flanking region of type-C human natriuretic peptide receptor gene influences blood pressure levels in obesity-associated hypertension. Hypertens Res. 2004;27(10): 711-716.
54. Brown J, Zuo Z. Receptor proteins and biological effects of C-type natriuretic peptides in the renal glomerulus of the rat. Am J Physiol. 1994; 266(4 pt 2): R1383-R1394.
55. Lam CS, et al. Influence of sex and hormone status on circulating natriuretic peptides. J Am Coll Cardiol. 2011;58(6): 618-626.
56. Khambata RS, Panayiotou CM, Hobbs AJ. Natriuretic peptide receptor-3 underpins the disparate regulation of endothelial and vascular smooth muscle cell proliferation by C-type natriuretic peptide. Br J Pharmacol. 2011;164(2b): 584-597.
57. Newby AC. Metalloproteinase expression in monocytes and macrophages and its relationship to atherosclerotic plaque instability. Arterioscler Thromb Vasc Biol. 2008;28(12): 2108-2114.
58. Thompson RW, et al. Production and localization of 92-kilodalton gelatinase in abdominal aortic aneurysms. An elastolytic metalloproteinase expressed by aneurysm-infiltrating macrophages. J Clin Invest. 1995;96(1): 318-326.
59. Goodall S, Crowther M, Hemingway DM, Bell PR, Thompson MM. Ubiquitous elevation of matrix metalloproteinase-2 expression in the vasculature of patients with abdominal aneurysms. Circulation. 2001;104(3): 304-309.
60. Krejci P, et al. Interaction of fibroblast growth factor and C-natriuretic peptide signaling in regulation of chondrocyte proliferation and extracellular matrix homeostasis. J Cell Sci. 2005;118(pt 21): 5089-5100.
61. Hu P, Wang J, Zhao XQ, Hu B, Lu L, Qin YH. Overexpressed C-type natriuretic peptide serves as an early compensatory response to counteract extracellular matrix remodeling in unilateral ureteral obstruction rats. Mol Biol Rep. 2013;40(2): 1429-1441.
62. Kugiyama K, Sugiyama S, Matsumura T, Ohta Y, Doi H, Yasue H. Suppression of atherosclerotic changes in cholesterol-fed rabbits treated with an oral inhibitor of neutral endopeptidase 24.11 (EC 3.4.24.11). Arterioscler Thromb Vasc Biol. 1996;16(8): 1080-1087.
63. Casco VH, Veinot JP, Kuroski de Bold ML, Masters RG, Stevenson MM, de Bold AJ. Natriuretic peptide system gene expression in human coronary arteries. J Histochem Cytochem. 2002;50(6): 799-809.
64. Kohno M, et al. Effect of natriuretic peptide family on the oxidized LDL-induced migration of human coronary artery smooth muscle cells. Circ Res. 1997;81(4): 585-590.
65. Furuya M, et al. C-type natriuretic peptide is a growth inhibitor of rat vascular smooth muscle cells. Biochem Biophys Res Commun. 1991;177(3): 927-931.
66. Cahill PA, Hassid A. Clearance receptor-binding atrial natriuretic peptides inhibit mitogenesis and proliferation of rat aortic smooth muscle cells. Biochem Biophys Res Commun. 1991;179(3): 1606-1613.
67. Daugherty A, Cassis LA. Mouse models of abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol. 2004;24(3): 429-434.
68. Pleumeekers HJ, et al. Aneurysms of the abdominal aorta in older adults. The Rotterdam Study. Am J Epidemiol. 1995;142(12): 1291-1299.
69. Blakeney JS, Reid RC, Le GT, Fairlie DP. Nonpeptidic ligands for peptide-activated G protein-coupled receptors. Chem Rev. 2007;107(7): 2960-3041.
70. Mason JS, Bortolato A, Congreve M, Marshall FH. New insights from structural biology into the druggability of G protein-coupled receptors. Trends Pharmacol Sci. 2012;33(5): 249-260.
71. Cheng AC, et al. Structure-based maximal affinity model predicts small-molecule druggability. Nat Biotech. 2007;25(1): 71-75.
72. Kisanuki YY, Hammer RE, Miyazaki J, Williams SC, Richardson JA, Yanagisawa M. Tie2-Cre transgenic mice: a new model for endothelial cell-lineage analysis in vivo. Dev Biol. 2001;230(2): 230-242.
73. Zuberi Z, Birnbaumer L, Tinker A. The role of inhibitory heterotrimeric G proteins in the control of in vivo heart rate dynamics. Am J Physiol Regul Integr Comp Physiol. 2008;295(6): R1822-R1830.
74. Ahluwalia A, et al. Antiinflammatory activity of soluble guanylate cyclase: cGMP-dependent down-regulation of P-selectin expression and leukocyte recruitment. Proc Natl Acad Sci U S A. 2004;101(5): 1386-1391.
75. Laxton RC, et al. A role of matrix metalloproteinase- 8 in atherosclerosis. Circ Res. 2009;105(9): 921-929.